Mass General Hospital

Harvard Medical School

Welcome to the MGH Center for Women’s Mental Health

Welcome to the Massachusetts General Hospital Center for Women’s Mental Health, a perinatal and reproductive psychiatry information center.

This website provides a range of current information including discussion of new research findings in women’s mental health and how such investigations inform day-to-day clinical practice. Despite the growing number of studies being conducted in women’s health, the clinical implications of such work are frequently controversial, leaving patients with questions regarding the most appropriate path to follow. Providing these resources to patients and their doctors so that individual clinical decisions can be made in a thoughtful and collaborative fashion dovetails with the mission of our Center.

We hope you find this website informative and we welcome your comments.

The National Pregnancy Registry for Atypical Antipsychotics:

All pregnant women ages 18-45 are eligible to enroll in the registry. We are currently seeking both controls and those being treated with one or more of the following atypical antipsychotics: 

  • Abilify (aripiprazole)
  • Clozaril (clozapine)
  • Geodon (ziprasidone)
  • Invega (paliperidone)
  • Latuda (lurasidone)
  • Risperdal (risperidone)
  • Saphris (asenapine)
  • Seroquel (quetiapine)
  • Zyprexa (olanzapine)

Register now by calling 1-866-961-2388 and help make the future better for many other women just like you.

This study will involve 3 brief phone interviews over an 8-month period. The National Pregnancy Registry for Atypical Antipsychotics is dedicated to evaluating the safety of atypical antipsychotic medications that may be taken by women during pregnancy to treat a wide range of mood, anxiety, or psychiatric disorders. The primary goal of this Registry is to determine the frequency of major malformations, such as heart defects, cleft lip, or neural tube defects, in infants exposed to atypical antipsychotics during pregnancy. For more information, please call 1-866-961-2388.

The MGH Center for Women’s Mental Health
Perinatal and Reproductive Psychiatry Program
Simches Research Builiding
185 Cambridge St Suite 2200
Boston, MA 02114

To make an appointment:

Massachusetts General Hospital Clinical Program: (617) 724-7792

Latest News from our Blog

  • Opioid Prescriptions among Women of Reproductive Age (2008–2012): A Growing Problem

    January 23, 2015

    woman-thinking-window

    This report from the Centers for Disease Control (CDC) was published yesterday and is a good, albeit alarming, companion to the post we published yesterday on obstetrical outcomes.

    Read more
  • Opioid Abuse and Dependence in Pregnancy: Impact on Obstetrical Outcomes

    January 22, 2015

    ultrasound

    In a recent study, researchers looked at the rising nationwide trend of opioid abuse and dependence in pregnancy and obstetrical outcomes in this patient population.  Previous research has focused on neonatal outcomes, such as neonatal abstinence syndrome; however, maternal complications have not been well-studied.  In this study, data was collected from the Nationwide Inpatient Sample ...

    Read more
  • Folic Acid is Essential for All Women of Reproductive Age

    January 19, 2015

    woman-pregnant

    Last week was National Folic Acid Awareness Week at the Centers for Disease Control (CDC), so this seems like a great time to remind women (and their caregivers) of the importance of folic acid in the prevention of birth defects. By taking the recommended dosage of folic acid daily, women will reduce the risk of neural tube ...

    Read more
  • Avoid Valproic Acid in Women of Reproductive Age

    January 16, 2015

    woman-thinking-yellow-shirt

    The European Medicine Agency (EMA)’s Pharmacovigilance and Risk Assessment Committee recently recommended strengthening the restrictions on the use of valproic acid in women of reproductive age.  Over the last few years, we have seen a host of articles documenting the deleterious effects of valproic acid on the developing fetus:

    Read more
  • Pilot Study: Omega-3 Fatty Acids Decrease Levels of Stress during Pregnancy

    January 15, 2015

    woman-face

    We have long been concerned about the impact of stressful life events on pregnancy outcomes.  There is data to indicate that stress experienced during pregnancy may increase the risk of various adverse outcomes, including increased risk of preterm birth and lower birth weight. Other studies suggest that prenatal exposure to maternal stress may also increase ...

    Read more
  • Happy New Year: Let’s Start By Taking a Look Back to 2014

    January 8, 2015

    concerned-mother-baby

    2014 was a huge year in the field of Reproductive Psychiatry.  Never before have we seen so many articles published in this specialty.  Much attention has focused on the reproductive safety of psychotropic medication; however, we have seen an increased interest in the mental health of women and a greater appreciation of how psychiatric illness ...

    Read more
  • Perinatal Dyadic Psychotherapy for the Treatment of Postpartum Depression

    December 28, 2014

    kissing-baby

    Many studies have observed that postpartum depression may negatively affect the mother-infant relationship and may thus impede bonding and attachment and negatively affect the development of the young child.  A recent study explores the use of Perinatal Dyadic Psychotherapy (PDP), a dual-focused mother-infant intervention designed to prevent and/or decrease depressive symptoms in the mother and ...

    Read more
  • Women with Epilepsy at Higher Risk for Perinatal Depression

    December 23, 2014

    woman-in-field

    A recent study examined the prevalence and risk factors for perinatal depression and anxiety in a group of Norwegian women with epilepsy (n = 706) compared to pregnancies in all women without epilepsy (n = 106,511).

    Read more
  • Acupuncture for Postpartum Depression

    December 22, 2014

    concerned-mother-baby

    85 women with postpartum depression were randomized to receive acupuncture plus psychological intervention (five sessions per week) or treatment with fluoxetine (20 mg per day). The two groups were treated continuously for six weeks. Depressive symptoms were measured using the Hamilton Depression scale (HAMD).

    Read more
  • The Impact of Infertility Treatment on Mood: Some Women are More Vulnerable

    December 16, 2014

    woman-praying

    While many women complain of psychological distress during infertility treatment, it has been somewhat unclear if the anxiety and depression women may experience is related to having to undergo infertility treatment or to the hormonal agents that are used as part of the treatment, or a combination of the two.   While we know that changing ...

    Read more

Read more from our Blog